Murray CJ, Ortblad KF, Guinovart C, Lim SS, Wolock TM, Roberts DA, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014;384(9947):1005–70.
Wang H, Wolock TM, Carter A, Nguyen G, Kyu HH, Gakidou E, et al. Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2015: the Global Burden of Disease Study 2015. Lancet HIV. 2016;3(8):e361–87.
HIVAIDS. JUNPo. Report on the global acquired immunodeficiency syndrome epidemic. Geneva: UNAIDS; 2008.
GhanaAIDS. 2019 HIV Sentinel Survey Report. Ghana AIDS Commission; 2019.
Jamieson D, Kellerman SE. The 90 90 90 strategy to end the HIV Pandemic by 2030: can the supply chain handle it? J Int AIDS Soc. 2016;19(1):20917.
HIV/AIDS. JUNPo. Geneva: UNAIDS; 2018.
HIV UG. AIDS statistics—2018 fact sheet. Geneva: UNAIDS; 2019.
Barry O, Powell J, Renner L, Bonney EY, Prin M, Ampofo W, et al. Effectiveness of first-line antiretroviral therapy and correlates of longitudinal changes in CD4 and viral load among HIV-infected children in Ghana. BMC Infect Dis. 2013;13(1):476.
Smith C, Phillips A, Dauer B, Johnson M, Lampe F, Youle M, et al. Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression. HIV Med. 2009;10(1):19–27.
Havlir DV, Hellmann NS, Petropoulos CJ, Whitcomb JM, Collier AC, Hirsch MS, et al. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA. 2000;283(2):229–34.
Maina E, Mureithi H, Adan A, Muriuki J, Lwembe R, Bukusi E. Incidences and factors associated with viral suppression or rebound among HIV patients on combination antiretroviral therapy from three counties in Kenya. Int J Infect Dis. 2020;97:151–8.
Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, et al. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.
Kassa D, Gebremichael G, Alemayehu Y, Wolday D, Messele T, van Baarle D, et al. Virologic and immunologic outcome of HAART in Human Immunodeficiency Virus (HIV)-1 infected patients with and without tuberculosis (TB) and latent TB infection (LTBI) in Addis Ababa, Ethiopia. AIDS Res Ther. 2013;10(1):18.
Horter S, Thabede Z, Dlamini V, Bernays S, Stringer B, Mazibuko S, et al. “Life is so easy on ART, once you accept it”: acceptance, denial and linkage to HIV care in Shiselweni, Swaziland. Soc Sci Med. 2017;176:52–9.
UNAIDS. Factsheet: global AIDS update. Geneva: UNAIDS; 2019.
Craw JA, Beer L, Tie Y, Jaenicke T, Shouse RL, Prejean J. Viral rebound among persons with diagnosed HIV who achieved viral suppression. JAIDS: United States; 2020.
Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine. 2018;97(22):e10562. https://doi.org/10.1097/md.0000000000010562.
Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, et al. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy. Antivir Ther. 2008;13(7):927–36.
Adams JW, Marshall BD, Salleh NAM, Barrios R, Nolan S, Milloy M-J. Receipt of opioid agonist treatment halves the risk of HIV-1 RNA viral load rebound through improved ART adherence for HIV-infected women who use illicit drugs. Drug Alcohol Depend. 2020;206: 107670.
Schmidt D, Kollan C, Stoll M, Hamouda O, Bremer V, Kurth T, et al. Everything counts-a method to determine viral suppression among people living with HIV using longitudinal data for the HIV care continuum-results of two large, German, multi-center real-life cohort studies over 20 years (1999–2018). BMC Public Health. 2021;21(1):1–17.
Landovitz R. What’s the best way to measure ART adherence, vol. 3. Massachusetts: Journal Watch; 2011. p. 23.
Suryana K, Suharsono H, Antara IGPJ. Factors associated with adherence to anti-retroviral therapy among people living with HIV/AIDS at Wangaya Hospital in Denpasar, Bali, Indonesia: a cross-sectional study. HIV AIDS. 2019;11:307.
O’Connor J, Smith C, Lampe FC, Johnson MA, Chadwick DR, Nelson M, et al. Durability of viral suppression with first-line antiretroviral therapy in patients with HIV in the UK: an observational cohort study. Lancet HIV. 2017;4(7):e295–302.
HIV/AIDS. Epidemiological fact sheets on HIV/AIDS and sexually transmitted infections. Geneva: WHO; 2004.
UNAIDS. UNAIDS data. Geneva: UNAIDS; 2018. p. 2018.
Bezabhe WM, Chalmers L, Bereznicki LR, Peterson GM. Adherence to antiretroviral therapy and virologic failure: a meta-analysis. Medicine. 2016. https://doi.org/10.1097/MD.0000000000003361.
WHO. Key facts on HIV/AIDS. Geneva: WHO; 2018.
Lebelonyane R, Bachanas P, Block L, Ussery F, Alwano MG, Marukutira T, et al. To achieve 95–95-95 targets we must reach men and youth: high level of knowledge of HIV status, ART coverage, and viral suppression in the Botswana Combination Prevention Project through universal test and treat approach. PLoS ONE. 2021;16(8): e0255227. https://doi.org/10.1371/journal.pone.0255227.
Koss CA, Natureeba P, Kwarisiima D, Ogena M, Clark TD, Olwoch P, et al. Viral suppression and retention in care up to 5 years after initiation of lifelong ART during pregnancy (option B+) in rural Uganda. J Acquir Immune Defic Syndr. 2017;74(3):279–84. https://doi.org/10.1097/QAI.0000000000001228.
Lokpo SY, Ofori-Attah PJ, Ameke LS, Obirikorang C, Orish VN, Kpene GE, et al. Viral suppression and its associated factors in HIV patients on highly active antiretroviral therapy (HAART): a retrospective study in the Ho Municipality, Ghana. AIDS Res Treat. 2020;2020:9247451. https://doi.org/10.1155/2020/9247451.
Kiselinova M, Geretti AM, Malatinkova E, Vervisch K, Beloukas A, Messiaen P, et al. HIV-1 RNA and HIV-1 DNA persistence during suppressive ART with PI-based or nevirapine-based regimens. J Antimicrob Chemother. 2015;70(12):3311–6. https://doi.org/10.1093/jac/dkv250.
Resino S, Resino R, Micheloud D, Gurbindo-Gutiérrez D, Léon JA, Ramos JT, et al. Long-term effects of highly active antiretroviral therapy in pretreated, vertically HIV type 1-infected children: 6 years of follow-up. Clin Infect Dis. 2006;42(6):862–9.
Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, et al. Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clin Infect Dis. 2002;34(4):504–10.
Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349(11):1036–46.
Maman D, Zeh C, Mukui I, Kirubi B, Masson S, Opolo V, et al. Cascade of HIV care and population viral suppression in a high-burden region of Kenya. AIDS. 2015;29(12):1557.
Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine. 2018. https://doi.org/10.1097/MD.0000000000010562.
Craw JA, Beer L, Tie Y, Jaenicke T, Shouse RL, Prejean J. Viral rebound among persons with diagnosed HIV who achieved viral suppression, United States. J Acquir Immune Defic Syndr. 2020;84(2):133–40. https://doi.org/10.1097/QAI.0000000000002321.
Dessie ZG, Zewotir T, Mwambi H, North D. Modeling viral suppression, viral rebound and state-specific duration of HIV patients with CD4 count adjustment: parametric multistate frailty model approach. Infect Dis Ther. 2020;9(2):367–88.
Bulage L, Ssewanyana I, Nankabirwa V, Nsubuga F, Kihembo C, Pande G, et al. Factors associated with virological non-suppression among HIV-positive patients on antiretroviral therapy in Uganda, August 2014–July 2015. BMC Infect Dis. 2017;17(1):1–11.
Palmer A, Gabler K, Rachlis B, Ding E, Chia J, Bacani N, et al. Viral suppression and viral rebound among young adults living with HIV in Canada. Medicine. 2018;97(22):e10562. https://doi.org/10.1097/MD.0000000000010562.
Ren L, Li J, Zhou S, Xia X, Xie Z, Liu P, et al. Prognosis of HIV patients receiving antiretroviral therapy according to CD4 counts: a long-term follow-up study in Yunnan, China. Sci Rep. 2017;7(1):9595. https://doi.org/10.1038/s41598-017-10105-7.
Meresse M, March L, Kouanfack C, Bonono RC, Boyer S, Laborde-Balen G, et al. Patterns of adherence to antiretroviral therapy and HIV drug resistance over time in the Stratall ANRS 12110/ESTHER trial in Cameroon. HIV Med. 2014;15(8):478–87. https://doi.org/10.1111/hiv.12140.